Tesamorelin

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the brain peptide that signals the pituitary gland to release growth hormone (GH). It carries a small chemical modification that makes it more stable and potent than natural GHRH. ¹

The drug is FDA-approved (as Egrifta) for reducing excess abdominal visceral fat in adults with HIV and lipodystrophy, a condition of abnormal fat distribution linked to antiretroviral therapy. ²⁸ The approval rested on two phase 3 trials showing a 15.4% greater reduction in visceral adipose tissue than placebo at 26 weeks. ¹ Two independent meta-analyses confirm these effects. ²

Beyond the approved use, randomized trials have tested tesamorelin for liver fat in HIV-associated fatty liver disease, ⁴ for muscle quality, ¹⁰ and for cognition in mild cognitive impairment and healthy aging. ⁶ Early work also explores preserving lean mass during weight loss, but that evidence is not yet mature. ²⁶

Tesamorelin binds and activates the GHRH receptor on somatotroph cells in the anterior pituitary gland. ¹ This receptor normally responds to pulses of natural GHRH; activating it raises the second messenger cyclic AMP and triggers bursts of growth hormone (GH) release. Because tesamorelin works through the receptor rather than supplying GH directly, growth hormone secretion stays pulsatile and governed by the body's own feedback loops, mainly through insulin-like growth factor 1 (IGF-1). ²⁴

IGF-1 is the main downstream effector. In phase 3 trials at 2 mg daily, mean IGF-1 rose by about 108 ng/mL. ¹ The 1 mg cognitive trial in older adults raised IGF-1 by 117% while keeping it within the physiological range. ⁶

Visceral fat selectivity is the defining feature. The visceral depot responds more strongly to GH/IGF-1 signaling than subcutaneous fat, so tesamorelin reduces deep belly fat while sparing the fat under the skin. ¹ Pooled RCT data show visceral adipose tissue reduction of about 27.7 cm² and lean body mass gain of 1.42 kg. ²

Secondary mechanisms in the liver and elsewhere are documented in biopsy and imaging studies: 12 months reduced liver fat by 37% relative to baseline, corresponding to a -4.1% absolute reduction versus placebo, ⁴ and liver biopsy gene sets showed upregulation of energy-producing oxidative phosphorylation and downregulation of inflammatory, repair, and cell-division pathways. ¹² Muscle imaging in responders showed increased density and area of trunk muscles. ¹⁰ Brain imaging in the cognitive trial showed increased GABA and decreased myo-inositol in certain regions. ⁶

Documented effects, with evidence strength:

• Visceral fat reduction: 15.4% treatment effect at 26 weeks in phase 3; sustained to -17.5% at 52 weeks with continued dosing. Meta-analysis confirms -27.7 cm². ¹
• Liver fat: 12-month RCT reduced hepatic fat fraction by 4.1% absolute (37% relative), with 35% of treated participants reaching <5% liver fat vs 4% on placebo. ⁴
• Hepatic fibrosis: In the same 12-month biopsy-based RCT, tesamorelin prevented hepatic fibrosis progression over 12 months.
• Liver transaminases: Among tesamorelin responders with elevated baseline ALT/AST, ALT and AST improved significantly versus nonresponders.
• CD4+ T-cell counts: Meta-analysis found no significant change in CD4+ T-cell counts during tesamorelin treatment.
• Lean mass and muscle quality: +1.42 kg lean body mass; CT showed increased muscle density and area in responders. ²
• Triglycerides and cholesterol: Triglycerides fell 12.3% vs placebo; total and non-HDL cholesterol improved in type 2 diabetes. ¹
• Cognitive function: One 20-week RCT in older adults found improved executive function (P=.005), but later trials in HIV and a 10-week pilot did not replicate. ⁶
• Glycemic safety: No clinically meaningful change in glucose parameters in phase 3 or in a dedicated type 2 diabetes trial, though a transient week-2 fasting glucose rise occurred. ¹
• Cardiometabolic risk: Modeled 10-year ASCVD risk trended lower, driven by cholesterol. ¹⁴

Research protocols are summarized; the most common is 2 mg subcutaneously once daily, derived from the FDA-approved phase 3 program. ¹ Trials ran 26 weeks with extension to 52 weeks. A second dose, 1 mg daily, was studied for cognition in older adults for 20 weeks. ⁶ Both doses are fixed, not weight-adjusted. ¹

Protocol	Dose	Duration	Evidence
Phase 3 visceral fat reduction	2 mg SC daily	26-52 weeks	Phase 3 RCT 1
HIV NAFLD	2 mg SC daily	12 months	RCT 4
Cognition / MCI	1 mg SC daily	20 weeks	RCT 6
Type 2 diabetes safety	1 or 2 mg SC daily	12 weeks	RCT 7
Exercise adjunct (TRIUMPH)	Dose not specified in protocol abstract; 2 mg SC daily presumed/standard + exercise	24 weeks	Ongoing 27

Community protocols sometimes use 1-2 mg daily with periodic off days, but no randomized trial has compared these schedules to daily dosing. [community protocol]

Tesamorelin is supplied as a lyophilized (freeze-dried) powder that must be reconstituted before subcutaneous injection. ¹ Two approved pharmaceutical formulations exist: the original Egrifta at 1 mg/mL and the concentrated Egrifta WR at about 8 mg/mL, shown to be bioequivalent. ¹⁹

Bacteriostatic water is the standard diluent. Community protocols call for injecting the diluent slowly against the vial wall and swirling gently; do not shake because tesamorelin is a lipidated peptide that can foam and lose potency with agitation. [community protocol]

Storage: keep lyophilized powder refrigerated (2-8°C) or frozen for long-term; after reconstitution, store in the refrigerator and use within 14-28 days. Do not refreeze reconstituted solution. [community protocol] The molecule is sensitive to temperature and pH, so minimize time at room temperature. ³⁵ Refer to the interactive calculator below to work out specific volumes and concentrations for your vial.

Formal interaction studies are limited but reassuring. Co-administration with simvastatin or ritonavir produced no clinically meaningful effect on CYP3A4 drug metabolism, so no dose adjustment is required. ²⁰ A 12-week trial in type 2 diabetes found no worsening of glycemic control when tesamorelin was added to usual diabetes care. ⁷

With antiretroviral therapy, tesamorelin has been used throughout the development program, and a subgroup analysis of integrase inhibitor users showed retained efficacy without excess hyperglycemia. ¹⁵

Peptide-peptide interactions: Tesamorelin acts on the GHRH receptor, which is more selective than ghrelin-mimetic secretagogues. Combining with other GH-axis stimulators (CJC-1295, ipamorelin, GHRP-2) is redundant and likely multiplies side effects without added benefit. ³¹ A case series documents combined use with GLP-1 receptor agonists in HIV-associated central adiposity, where tesamorelin added targeted visceral fat reduction after inadequate GLP-1 response. ¹⁷ Regenerative peptides such as BPC-157 and TB-500 act through different pathways; no pharmacological interaction is documented, but human evidence for those agents remains limited. ²⁹

No randomized trial has tested deliberate on/off cycling. The studied paradigm is continuous daily subcutaneous dosing: 26 weeks in phase 3, 12 months in the NAFLD trial, and 20 weeks in the cognition study. ¹ The phase 3 design included a discontinuation arm, and participants switched to placebo reaccumulated visceral fat over 26 weeks. ¹ This shows the benefit requires continued dosing and that stopping does not cause withdrawal symptoms.

Community schedules often use 5 days on / 2 days off within 12-26 week blocks, followed by 4-8 weeks off. [community protocol] The rationale is to manage exposure, side effects, cost, and to let IGF-1 return toward baseline. No trial data support this pattern over continuous dosing, but no tachyphylaxis (loss of effect) was seen over 52 weeks of continuous use. ¹

Signs for a break might include sustained IGF-1 above the age-adjusted range, new or progressive joint/muscle pain, hand numbness, or persistent injection-site reactions. ²

Common combinations in gray-market use include other GH secretagogues such as ipamorelin or CJC-1295, marketed for recovery and recomposition. ²² However, all these agents act on the same GH axis, so stacking multiplies IGF-1 elevation and shared side effects (joint pain, fluid retention, glucose changes) without evidence of added benefit. ³¹

A more rationale combination in the literature is tesamorelin with a GLP-1 receptor agonist, where mechanisms are complementary: the GLP-1 drug produces general weight loss while tesamorelin selectively reduces visceral fat. A case report in HIV-associated central adiposity documents this sequential approach. ¹⁷

For musculoskeletal recovery, some users stack tesamorelin with regenerative peptides like BPC-157 or TB-500. These act through different pathways, and no pharmacological interaction is known, but the evidence for the regenerative peptides themselves is largely preclinical. ²⁹ Athletes subject to anti-doping rules should note that tesamorelin is WADA-prohibited and detectable in urine. ²³

Tesamorelin was approved by the FDA in November 2010 for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy; it remains the only approved therapy for this indication. ²⁸ The approval is indication-specific: no approval exists for body recomposition, performance, anti-aging, or musculoskeletal recovery, and reviews classify those uses as lacking an approved evidentiary basis. ²²

Outside the United States, no EMA, MHRA, or TGA marketing authorization is documented, so access occurs through unregulated supply chains. ²² Tesamorelin is not scheduled under the US Controlled Substances Act.

Sports status: GHRH and analogues including tesamorelin are prohibited by WADA at all times. Validated urine detection limits reach 0.5 ng/mL or lower, and plasma methods detect below 50 pg/mL. ²³

The most common adverse events in phase 3 trials were injection-site reactions, arthralgia (joint pain), myalgia (muscle pain), and paresthesia (tingling). ¹ These are generally mild and self-limited. The concentrated Egrifta WR formulation reduces injection-site pain compared to the original. ¹⁹

Glycemic safety: a transient fasting glucose rise of about 7 mg/dL appeared at week 2 of one trial but resolved by 6 months; a dedicated 12-week trial in type 2 diabetes found no change in HbA1c or diabetes control. ⁵

Pharmacovigilance signals: postmarketing reports show an elevated reporting rate for carpal tunnel syndrome (ROR 20.7), but causality has not been confirmed in prospective trials. ¹⁶

Contraindications include pregnancy and active malignancy. ³¹ Discontinuation rates trend higher than placebo (RR 2.25), driven by GH-related adverse effects. ³ Long-term safety beyond 52 weeks is uncharacterized. ¹